These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 34332798)

  • 1. Cutaneous adverse events caused by immune checkpoint inhibitors.
    Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
    J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.
    Pach J; Leventhal JS
    Crit Rev Immunol; 2022; 42(4):1-20. PubMed ID: 37022356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
    Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucocutaneous adverse events to immune checkpoint inhibitors.
    Muhaj F; Karri PV; Moody W; Brown A; Patel AB
    Front Allergy; 2023; 4():1147513. PubMed ID: 36938327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
    Storgard R; Markova A
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous manifestations associated with immune checkpoint inhibitors.
    Watanabe T; Yamaguchi Y
    Front Immunol; 2023; 14():1071983. PubMed ID: 36891313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
    Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
    J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of immune checkpoint inhibitor-related dermatologic adverse events.
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients.
    Alexandris D; Alevizopoulos N; Gakiopoulou H; Stavrinou N; Vourlakou C
    J Oncol Pharm Pract; 2022 Jul; 28(5):1276-1282. PubMed ID: 35038934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous immune-related adverse events to checkpoint inhibitors.
    Malviya N; Tattersall IW; Leventhal J; Alloo A
    Clin Dermatol; 2020; 38(6):660-678. PubMed ID: 33341200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing immune checkpoint inhibitor-related cutaneous adverse reactions: A comprehensive analysis of FDA adverse event reporting system (FAERS) database.
    Esen BH; Özbek L; Oğuz S; Selçukbiricik F
    Heliyon; 2024 Jul; 10(13):e33765. PubMed ID: 39071598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
    Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
    J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
    Pach J; Valido K; Belzer A; Leventhal JS
    Am J Clin Dermatol; 2024 Jul; 25(4):595-607. PubMed ID: 38767827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.